2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 535

Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies
Abstract Number: 2941

Effect of Achieving Sustained SDAI Remission on Erosion Repair in Patients with Early RA: A Prospective HR-pQCT Study
Abstract Number: 636

Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Abstract Number: 1900

Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Abstract Number: 1707

Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Abstract Number: 654

Effect of Anti Tnfα Drugs on the Frequency of Circulating CD19+CD24hiCD38hi Breg Cells in Ankylosing Spondylitis
Abstract Number: 1220

Effect of Anti-Diabetic Medications on Fracture Risk in Type II Diabetes Mellitus
Abstract Number: 2924

Effect of Antimalarials over the Different Domains of the Damage INDEX in Latin American SLE Patients
Abstract Number: 2756

Effect of Baseline and Change in Effusion-Synovitis on Cartilage Damage over 18 Months in Patients with Osteoarthritis and Meniscal Tear
Abstract Number: 534

Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study
Abstract Number: 1108

Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Abstract Number: 1888

Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals
Abstract Number: 2379

Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Abstract Number: 1951

Effect of Initiating Metformin Vs. Sulfonylureas on the Risk of Total Knee Arthroplasty
Abstract Number: 1445

Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].